Prévisions

L'objectif de cours moyen des analystes est de 12,05 € (+145,92 %). La médiane est de 12,05 € (+145,92 %).

Acheter	15
Conserver	3
Vendre	0

Actualités Accéder au fil d'actualités

Taysha Gene Therapies reports larger-than-expected quarterly loss and stock falls

Taysha reported an EPS loss of $0.13 in Q2 versus a consensus of $0.12, prompting an after-hours sell-off of about 7.0%. The net loss widened to $46.6 million from $26.9 million a year earlier, driven by increased R&D and administrative expenses related to process qualification and patient recruitment for the REVEAL and ASPIRE studies. The company closed the quarter with $455.4 million in cash following a $230.0 million follow-on financing in June. Positively, TSHA-102 was well tolerated in 33 treated patients, but the market focus is now on cash burn ahead of the expected 2027 milestones. » Plus sur de.investing.com
Taysha secures commercial manufacturing agreement with Catalent for TSHA-102

Taysha has signed a commercial manufacturing agreement with Catalent for the gene therapy TSHA-102 to treat Rett syndrome; Catalent is to act as the primary commercial manufacturer upon potential FDA approval. Catalent will handle GMP-compliant production and commercial supply at its licensed facility in Harmans, Maryland; the companies have collaborated since 2020. Process qualification activities for TSHA-102 are currently underway as part of the BLA. » Plus sur de.investing.com
Taysha Gene Therapies stock climbs to new all-time high at 5.49 USD

Taysha Gene Therapies’ stock reached a new all-time high of 5.49 USD but remains below its 52-week high of 7.30 USD and fell nearly 8% on the week. Over the past year the share price rose by almost 100%, while InvestingPro classifies the stock as overvalued. For Q1 2026 Taysha reported a net loss of 0.12 USD per share (expectation: -0.10 USD) and no revenues (expectation: 850,000 USD), yet showed slight strength in premarket trading. Investors are now watching the company’s strategic responses in light of missing revenue and missed forecasts. » Plus sur de.investing.com

Données financières de l'entreprise

Au dernier trimestre, TAYSHA GENE T. DL -,00001 a réalisé un chiffre d'affaires de 0 € et un bénéfice net de -40,87 M €

(EUR)	juin 2026	YoY
Chiffre d'affaires	0	100,00 %
Bénéfice brut	0	100,00 %
Bénéfice net	-40,87 M	79,18 %
EBITDA	-40,51 M	79,58 %

Données fondamentales

Indicateur	Valeur
Capitalisation boursière	1,59 Md €
Nombre d'actions	319,86 M
Plus haut/bas sur 52 semaines	6,28 € - 2,33 €
Dividendes	Non
Bêta	1,19
Ratio P/E	-13,65
Ratio PEG	0,83
Ratio P/B	5,50
Ratio P/S	336,48

Profil de l'entreprise

Taysha Gene Therapies, Inc. ist ein Gentherapie-Unternehmen, das sich auf die Entwicklung und Vermarktung von Gentherapien auf der Basis von Adeno-assoziierten Viren zur Behandlung von monogenen Erkrankungen des zentralen Nervensystems konzentriert. Das Unternehmen entwickelt in erster Linie TSHA-120 für die Behandlung der Riesenaxon-Neuropathie, TSHA-102 für die Behandlung des Rett-Syndroms, TSHA-121 für die Behandlung der CLN1-Krankheit, TSHA-118 für die Behandlung der CLN1-Krankheit, TSHA-105 für die Behandlung des SLC13A5-Mangels und TSHA-101 für die Behandlung der GM2-Gangliosidose. Taysha Gene Therapies, Inc. hat eine strategische Partnerschaft mit der University of Texas Southwestern Medical Center, um transformative Gentherapie-Behandlungen zu entwickeln und zu vermarkten. Das Unternehmen wurde im Jahr 2019 gegründet und hat seinen Sitz in Dallas, Texas.

Nom	TAYSHA GENE T. DL -,00001
PDG	Sean Nolan
Siège social	Dallas, tx États-Unis
Site web	tayshagtx.com
Secteur	Consommation de base
Industrie	Produits alimentaires
Introduction en bourse	18/06/2010
Employés	99